MedTrace Logo

NSAID Effects on Clinical and Imaging Breast Biomarkers

NCT01761877 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2023-02-10

Study results available
· View outcomes & findings →

Summary

This study has two purposes. One is to determine if daily sulindac decreases breast density; a risk factor for breast cancer development. The second is to determine whether sulindac reduces pain and stiffness associated with regular use of aromatase inhibitors given for the treatment of breast cancer.

Conditions

Interventions

DRUG

Sulindac

Sponsors & Collaborators

Principal Investigators

  • Patricia Thompson-Carino, PhD · Stony Brook University

  • Alison Stopeck, MD · Stony Brook University

  • Pavani Chalasani, MD · University of Arizona

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2019-02-07
Completion
2019-03-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01761877 on ClinicalTrials.gov